The natural history of human immunodeficiency virus infection in a haemophilic cohort

Christine A. Lee, Andrew Phillips,* Jonathan Elford,* Elizabeth J. Miller, Margarita Bofill,† Paul D. Griffiths‡ and Peter B. A. Kernoff *Haemophilia Centre and Haemostasis Unit, Academic Department of Haematology, *Department of Clinical Epidemiology and General Practice, †Academic Department of Immunology, ‡Department of Virology, Royal Free Hospital School of Medicine, London

Summary. 112 haemophilic patients infected with HIV were followed up with clinical and laboratory assessment between 1 December 1979 and 30 November 1988. Sixty-six (59%) of the patients developed HIV-related clinical symptoms and 22 (20%) developed AIDS. Twenty (18%) of the patients developed p24 antigenaemia. Amongst the 59 patients whose date of seroconversion could be estimated the calculated 8-year cumulative incidence of AIDS was 40% (symptoms 73%). For the whole cohort of 112 patients, the median slope of linear regression of the absolute T4 lympho-cyte count was steeper for those with AIDS (-0.113×10^9/l per year) than for those without AIDS (-0.054×10^9/l per year) ($P < 0.02$). While 15 cases of AIDS developed during 58 patient-years of follow up after falling below a T4 lymphocyte count of 0.2×10^9/l, only two cases occurred during 450 patient-years before reaching this count. Thus the decline of the T4 lymphocyte count to 0.2×10^9/l may be an appropriate additional end-point for the assessment of new treatments for asymptomatic patients infected with HIV.

Prediction of the course of the AIDS epidemic requires knowledge of the time interval from infection with the human immunodeficiency virus (HIV) to the development of AIDS. Actuarial progression rates to AIDS have been calculated in studies of patients both with and without known or estimated seroconversion dates (Moss & Bacchetti, 1989). The former group includes haemophiliacs, homosexual men and transfusion recipients.

Haemophiliacs have a high prevalence of antibody to human immunodeficiency virus (anti-HIV) as a result of treatment with unheated contaminated clotting factor concentrates (United Kingdom Haemophilia Directors, 1988). Of 525 haemophiliacs registered at the Royal Free Hospital Haemophilia Centre, 112 have been found to be anti-HIV positive. We describe here the development of symptoms related to HIV and the progression to AIDS in this population where detailed clinical and laboratory follow-up has been possible in a majority of patients from the time of seroconversion.

PATIENTS AND METHODS

Patients. 112 anti-HIV positive patients were entered into the study using data from records and samples from the period 1 December 1979 to 30 November 1988. 101 patients had severe haemophilia A (factor VIII <2 u/dl), seven moderate/mild haemophilia A (factor VIII >2 u/dl), one severe haemophilia B (factor IX <2 u/dl) and two von Willebrand's disease. One patient was the wife of a severely-affected haemophiliac and all other patients were male. Of the male patients, all except two had received treatment with unheated factor VIII concentrates; one had been treated with unheated factor IX concentrate and the other with cryoprecipitate. One patient regularly injected heroin intravenously. Treatment with heated concentrates was introduced in late 1984. Patients were reviewed for clinical and laboratory assessment at least every 6 months. Retrospective analyses were made of clinical records and stored serum samples.

From July 1987, 20 patients were started on treatment with zidovudine for advanced symptomatic HIV-related disease but the study period ended before any patients were entered into the Medical Research Council double-blind placebo controlled trial of zidovudine for asymptomatic patients (the Concorde 1 trial).

Laboratory methods. Antibody to HIV was measured using a competitive enzyme immunoassay (Wellcozyme, Wellcome Diagnostics, Dartford, England). HIV core antigen (p24) was measured by enzyme immunoassay (Abbott Diagnostics Division, Maidenhead, England). The absolute lymphocyte

Correspondence: Dr Christine A. Lee, Haemophilia Centre, Royal Free Hospital, London NW3 2QG.

Fig 1. 59 haemophiliacs with estimated dates of seroconversion. Open and closed circles denote negative and positive anti-HIV results, respectively.

Table I. HIV-related clinical symptoms in 66/112 (59%) anti-HIV positive haemophiliacs

Seborrhoeic dermatitis	22 (20%)
Oral candidiasis	17 (15%)
Bacterial infections	16 (14%)
Herpes zoster	11 (10%)
Thrombocytopenia	7 (6%)
Lymphadenopathy	7 (6%)

Table II. AIDS-presenting clinical features in 22/112 (20%) anti-HIV positive haemophiliacs

Pneumocystis pneumonia	11
HIV wasting syndrome	2
Non-Hodgkins lymphoma	3
Oesophageal candida	2
Aspergillus pneumonia	1
Cerebral toxoplasmosis	1
Chickenpox pneumonia (heroin addict)	1
Staphylococcal septicaemia (multiple cerebral abscesses)	1

Table III. Causes of death in 16 anti-HIV positive haemophiliacs

AIDS (11)	
Pneumocystis pneumonia	4
Non-Hodgkins lymphoma	2
Mycobacterium avium intracellulare (abdominal infection)	1
Aspergillus pneumonia	1
Chicken pox pneumonia (heroin addict)	1
HIV wasting syndrome	1
Staphylococcal septicaemia	1
Cirrhosis, liver failure	2
Cerebral haemorrhage	1
Suicide	1
Aspiration of vomit following an epileptic fit	1

count was determined using an automated whole blood counter (Ortho ELT 800 with a differential screen). The proportion of T4 lymphocytes was determined using a fluorescence activated cell sorter (Coulter EPICS V) after labelling the lymphocytes with monoclonal antibodies in the CD4 group: Leu-3a from Becton-Dickinson and RFT4 from the Royal Free Hospital Department of Immunology. Absolute T4 lymphocyte counting started in November 1982.

RESULTS

Seroconversion dates and clinical HIV related disease

In 59 patients for whom a previously negative anti-HIV result was available, the date of seroconversion could be estimated as the mid-point between the last negative and the first positive result. The median time interval between these two events was 11 months (range 16 d to 25 months), estimated dates of seroconversion spanning the years 1980–85 inclusive (Fig 1). In the remaining 53 patients the earliest available serum sample tested was anti-HIV positive. The earliest serum found to be anti-HIV positive was dated 12 December 1979; the last 'new' seroconversion was estimated to be July 1985. For the whole cohort, the median age at time of initial seropositivity was 24 years (range 2–77 years). The median time of follow-up was 5 years 5 months (range 1–9 years).

By 30 November 1988, 66/112 (59%) patients had

developed HIV related clinical symptoms (Table I). Thrombocytopenia, defined as a platelet count $<50 \times 10^9/l$, occurred in seven (6%) patients and two of these had developed AIDS. Bacterial infections included tonsillitis (6), otitis media (3), appendicitis (2), *E. coli* septicaemia (2), sinusitis (1), tooth abscess (1) and pneumococcal pneumonia (1). AIDS, classified according to the Centres for Diseases Control (CDC, 1987), had occurred in 22 (20%) patients (Table II). Eleven of the 16 deaths were due to AIDS (Table III).

p24 Antigenaemia

p24 antigenaemia was detected in 20 patients (18%) (Fig 2). Seven were p24 positive at the time of their first anti-HIV

Fig 2. p24 antigenaemia in 20 haemophiliacs. Open and closed squares denote negative and positive p24 results respectively. Open and closed circles denote negative and positive anti-HIV results. Patients with AIDS are indicated by an asterisk and those who have died are indicated †.

positive result, but the time to develop p24 after sero-conversion was variable in the remaining 13 patients. Eleven (55%) p24 positive patients developed AIDS at a median time interval of 2 years 3 months (range 2 months to 6 years 4 months) after first detection of p24 antigen. In contrast, only 11/92 (12%) p24 negative patients developed AIDS ($P<0.001$, chi-square test).

Progression to HIV-related clinical symptoms and AIDS

The methods of Kaplan-Meier were used to calculate cumulative incidence of clinical disease in the 59 patients with estimated dates of seroconversion. At 8 years the estimated cumulative probability of developing symptoms was 73% (95% confidence limits 58% and 88%) (Fig 3), and of developing AIDS 40% (95% confidence limits 30% and 50%) (Fig 4). These estimates were made for 8 years after seroconversion because only two patients had been sero-positive for 9 years. Lymphadenopathy as a symptom was excluded from the analysis because of difficulty in timing onset. The respective estimates for symptoms and AIDS are

also shown for the cohort stratified for age. The older group ($\geqslant 5$ years) had a significantly higher chance of developing symptoms ($P=0.002$ log rank test) and AIDS ($P=0.005$ log rank test).

T4 lymphocyte count and disease progression

The median number of measurements of absolute T4 lymphocytes for each of the 112 patients was seven (range 0–31). The relationship between the median T4 lymphocyte count and time since seroconversion is shown in Fig 5. When a linear regression model was fitted for each patient the median slope for the whole population was $-0.068 \times 10^9/l$ per year. The respective slopes for patients with and without AIDS were $-0.113 \times 10^9/l$ per year and $-0.054 \times 10^9/l$ per year ($P<0.02$, Wilcoxon two-sample test).

In an analysis of covariance the difference in mean minimum T4 lymphocyte counts between those patient with and without AIDS remained large and significant afte adjusting for years of sero-positivity ($0.21 \times 10^9/l$, $P=0.04$) In contrast, the difference in the mean number of years o

Fig 3. Estimated cumulative probability of developing HIV-related clinical symptoms in 59 anti-HIV positive haemophiliacs with known date of seroconversion.


Fig 4. Estimated cumulative probability of developing AIDS in 59 anti-HIV positive haemophiliacs with known date of seroconversion.

seropositivity between those with and without AIDS was small and non-significant after standardizing for T4 lymphocyte count (0·7 years, $P=0·39$).

The cumulative probability of developing HIV-related clinical symptoms or AIDS before falling to a given T4 count is shown in Table IV. For a given T4 count, the numerator for the probability is the number of patients diagnosed as having symptoms or AIDS while having a T4 count above this level. The denominator consists of all those in the numerator plus the number of patients who reached the T4 cut-off value symptom or AIDS-free. There was only a 50% chance of being symptom free at a T4 lymphocyte count of $0·2 \times 10^9/l$ and AIDS-free at a T4 lymphocyte count of $0·05 \times 10^9/l$.

The relationship between the T4 lymphocyte count and progression to AIDS was studied in relation to the total number of patient years of follow-up. There were 450 years before and 58 years after reaching a T4 lymphocyte count of $0·2 \times 10^9/l$. The numbers of AIDS cases in these groups were two and 15. This difference is highly significant ($P<0·0001$, Poisson model (IARC, 1987)).

The median T4 count by years from seroconversion is shown separately for patients aged less or more than 25 years in Fig 6. The rate of fall of T4 count is similar in the two age

groups, but the older patients had lower T4 counts at the time of seroconversion and therefore reached very low T4 counts more rapidly.

The fall in T4 lymphocyte count for patients who were p24 antigen positive at any time during follow-up in comparison with p24 antigen negative patients is shown in Fig 7. The fall was more rapid in the p24 positive patients.

DISCUSSION

The timing of the first seroconversion (1979) in this cohort correlated well with the beginning of the AIDS epidemic in homosexuals and intravenous drug users in the United States and similar observations have been made in American (Evatt *et al*, 1985) and French (Mathez *et al*, 1986) haemophilic populations. Heat-treated concentrates were introduced into our centre in late 1984 and there have been no new seroconversions since July 1985. As the period between HIV exposure and seroconversion is usually less than 14 weeks (Simmonds *et al*, 1988) and only occasionally exceeds 6 months (Ranki *et al*, 1987) we are optimistic that no new seroconversions will occur.

Previous estimates of the proportion of haemophiliacs

Fig 5. Median (10% and 90% percentiles) T4 lymphocyte counts from time of seroconversion.


Fig 6. Effect of age on median T4 lymphocyte count from time of seroconversion.

Table IV. Estimated cumulative probability of developing HIV-related symptoms and AIDS before falling to given T4 count levels

T4 count × 10⁹/l	Symptoms	AIDS
0·30	32% (18/56)	0% (0/48)
0·25	39% (21/54)	0% (0/43)
0·20	52% (29/56)	5% (2/39)
0·15	63% (34/54)	13% (4/32)
0·10	86% (42/49)	38% (9/24)
0·05	90% (43/48)	50% (10/20)
0·03	94% (47/50)	68% (13/19)
0·02	96% (47/49)	76% (13/17)
0·01	98% (47/48)	81% (13/16)

infected with HIV who progress to serious disease have been made difficult by the uncertain date of seroconversion (Eyster *et al*, 1987; Darby *et al*, 1989). Sophisticated statistical methods have therefore been used to estimate the time of infection (Giesecke *et al*, 1988) including the use of Weibull distributions (Medley *et al*, 1987). We followed the more usual approach of estimating the mid-point between the last negative and first positive anti-HIV results and limited the Kaplan-Meier analysis to the 59 patients in whom this was possible.

Haemophilic cohorts often permit a more precise definition

Fig 7. Median T4 lymphocyte count from time of seroconversion in p24 negative and positive haemophiliacs.

of the onset of clinical signs and symptoms of HIV infection than other at risk groups because haemophiliacs are usually under at least 6-monthly surveillance of their haemophilia (Eyster *et al*, 1987; Giesecke *et al*, 1988). Our estimate of the cumulative incidence of symptoms is similar to that for Swedish haemophiliacs, with 45% of patients developing symptoms at 5 years after seroconversion (Giesecke *et al*, 1988). Many of these symptoms require therapeutic intervention, underlining the enormous potential cost of health care in patients infected with HIV who have not yet progressed to AIDS. In contrast to others (Eyster *et al*, 1987), we did not find thrombocytopenia to be a strongly associated risk factor. The high incidence of bacterial infections, particularly of the head and neck, may reflect poor humoral immunity (Lane *et al*, 1983) and indicates the importance of prompt use of antibiotics in this patient group.

The estimated cumulative incidence of AIDS in our patient group, 40% at 8 years, was similar to that of Hessol *et al* (1988) for male homosexuals (37% at 8 years) but was somewhat higher than that of Goedert *et al* (1988) for American haemophiliacs (29% at 8 years) (Moss & Bacchetti, 1989). Nevertheless, all these studies confirm that the rate of progression from infection to AIDS is slow.

The p24 core protein of HIV is usually transiently detectable soon after initial infection, reappearing late in the disease (Allain *et al*, 1986; Goudsmit *et al*, 1986). In a minority of patients, however, HIV antigenaemia has persisted after primary infection (Pedersen *et al*, 1987). Our patients have demonstrated a varied pattern of p24 antigenaemia: occurrence at any time of seroconversion, persistence of antigenaemia, and recurrence both early and late in disease. It has been postulated that disappearance of HIV antigenaemia might follow the development of antibodies to p24 (Allain *et al*, 1986) individuals with persistent antigenaemia having defective humoral immunity (Lane *et al*, 1983). The recurrence of p24 antigenaemia during the course of HIV infection may be due to loss of anti-p24 (Pedersen *et al*, 1987). The transition from latent to active HIV infection or AIDS could also result from increased p24 antigen production which may depend on other co-factors such as cytomegalovirus (CMV) (Polk *et al*, 1987). In another study we have shown that haemophiliacs infected with CMV progress more rapidly to AIDS (Webster *et al*, 1989). Clearly, in our patients the presence of p24 antigen at any stage of HIV infection is associated with a worse prognosis.

We have not only confirmed the decline in the absolute T4 lymphocyte count with time lapsed since seroconversion (Moss & Bacchetti, 1989) but also established that this decline is greater in patients who develop AIDS. This, together with the analysis of covariance, suggests that the T4 lymphocyte count may be of greater predictive power than the duration of seropositivity. Although the T4 lymphocyte count is a coincident measure and may not predict well as a single measurement in individual situations we have found that the T4 counts taken over time provide a reliable basis for assessing the risk of developing symptoms of immune deficiency and AIDS. The more rapid fall of T4 lymphocyte counts in p24 positive patients may reflect faster replication of the virus in these individuals. We have shown, like others

(Moss & Bacchetti, 1989), that a depressed T4 lymphocyte count is essential for progression to AIDS. In particular, it is clear that the risk of developing AIDS is negligible until T4 lymphocyte counts fall to $0 \cdot 2 \times 10^9$/l. For this reason, when new treatments are assessed for asymptomatic patients the decline of the T4 lymphocyte count to $0 \cdot 2 \times 10^9$/l should be considered as an important indicator of the patient's condition, and the efficacy or otherwise of therapy.

In common with some other studies in haemophiliacs we found the cumulative incidence of symptoms and AIDS to be greater in older patients (Eyster *et al*, 1987; Darby *et al*, 1989); however, this is not a universal finding (Moss & Bacchetti, 1989). In our older patients the T4 lymphocyte count was lower at time of seroconversion, possibly reflecting a decline in T4 lymphocyte count with age irrespective of HIV infection (Falcao *et al*, 1987). Interestingly, the rates of fall of T4 lymphocyte count were similar in the two age groups.

This study was completed before any patients had entered the Medical Research Council double-blind placebo controlled trial of zidovudine in asymptomatic patients. The detailed description of HIV-related disease in this cohort will therefore provide a useful control for future drug trials in other asymptomatic at-risk groups. The cohort may also provide a basis for calculation of future health service needs in terms of care-provision and cost for HIV infected individuals.

REFERENCES

Allain, J.P., Laurian, Y., Paul, D.A. & Senn, D. (1986) Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs. *Lancet*, ii, 1233–1236.

CDC Revision of the CDC surveillance case definition for Acquired Immunodeficiency Syndrome (1987) *MMWR*, 36 (Suppl. 15), 1–157.

Darby, S.C., Rizza, C.R., Doll, R., Spooner, R.J.D., Stratton, I.M. & Thakrar, B. (1989) Seropositivity for HIV and incidence of AIDS and AIDS related complex in UK haemophiliacs: report on behalf of the directors of haemophilia centres in the UK. *British Medical Journal*, 298, 1064–1068.

Evatt, B.L., Gomperts, E.D., McDougal, J.S. & Ramsay, R. (1985) Coincidental appearance of LAV-1/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic. *New England Journal of Medicine*, 312, 483–486.

Eyster, M.E., Gail, M.H., Ballard, J.O., Al-Mondhiry, H. & Goedert, J.J. (1987) Natural history of human immunodeficiency virus. Infections in haemophiliacs: effects of T-cell subsets, platelet counts and age. *Annals of Internal Medicine*, 107, 1–6.

Falcao, R.P., Ismael, S.J. & Donadi, E.A. (1987) Age-associated changes of T lymphocyte subsets. *Diagnostic and Clinical Immunology*, 5, 205–208.

Giesecke, J., Scalia-Tomba, G., Berglund, O., Berntorp, E., Schulman, S. & Stigendal, L. (1988) Incidence of symptoms and AIDS in 146 Swedish haemophiliacs and blood transfusion recipients infected with human immunodeficiency virus. *British Medical Journal*, 297, 99–102.

Goudsmit, J., de Wolf, F., Paul, D.A., Epstein, L.G., Lange, J., Krone, W.J., Speelman, H., Wolters, E., Vander Noordaa, J., Oleshe, J.M., Van der Helm, H.J. & Coutinho, R.A. (1986) Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebro-spinal fluid during acute and chronic infection. *Lancet*, **ii**, 177–180.

International Agency for Research on Cancer (1987) *The Design and Analysis of Cohort Studies*, Chapter 4. WHO: IARC Scientific Publications no. 82, Lyon.

Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. *Journal of the American Statistical Association*, **53**, 457–481.

Lane, H.C., Masur, H., Edgar, L.C., Whaler, G., Rook, A.M. & Fauci, A.S. (1983) Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. *New England Journal of Medicine*, **309**, 453–458.

Mathez, D., Leibovitch, J., Sultan, Y. & Maisonneuve, P. (1986) LAV/HTLV-III seroconversion and disease in hemophiliacs treated in France. *New England Journal of Medicine*, **314**, 119–120.

Medley, G.F., Andersons, R.M., Cox, D.R. & Billard, L. (1987) Incubation period of AIDS in patients infected via blood transfusion. *Nature*, **328**, 719–721.

Moss, A.R. & Bacchetti, P. (1989) Natural history of HIV infection. *AIDS*, **3**, 55–61.

Pedersen, C., Nielsen, C.M., Vestergaard, B.F., Gerstoft, J., Krogs-gaard, K. & Nielsen, J.O. (1987) Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection. *British Medical Journal*, **295**, 567–569.

Polk, B.F., Fox, R., Brookmeyer, R., Kanchanaraksa, S., Kaslow, R., Visscher, B., Rinaldo, C. & Phair, J. (1987) Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. *New England Journal of Medicine*, **316**, 61–66.

Ranki, A., Valle, S.L., Krohn, M., Antonen, J., Allain, J.P., Leuther, M., Franchini, G. & Krohn, K. (1987) Long latency precedes overt seroconversion in sexually transmitted human-immunodeficiency-virus infection. *Lancet*, **ii**, 589–592.

Simmonds, P., Lainson, F.A., Cuthbert, R., Steel, C.M., Peutherer, J.F. & Ludlam, C.A. (1988) HIV antigen and antibody detection: variable responses to infection in the Edinburgh cohort. *British Medical Journal*, **296**, 593–598.

Webster, A., Lee, C.A., Cook, D.G., Grundyn, E., Emery, V.C., Kernoff, P.B.A. & Griffiths, P.D. (1989) Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection. *Lancet*, **ii**, 63–66.

AIDS group of the United Kingdom Haemophilia Centre directors with the co-operation of the United Kingdom haemophilia centre directors. (1988) Prevalence of antibody to HIV in haemophiliacs in the United Kingdom: a second survey. *Clinical and Laboratory Haematology*, **10**, 187–191.